Nautilus Biotechnology, Inc. (ARYA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Agenus, Inc.

AnaptysBio, Inc.

Janux Therapeutics, Inc.

Caribou Biosciences, Inc.

UroGen Pharma Ltd.

Avidity Biosciences, Inc.

Dyne Therapeutics, Inc.

Mineralys Therapeutics, Inc.

iTeos Therapeutics, Inc.

Nautilus Biotechnology, Inc.

AN2 Therapeutics, Inc.

Why is Nautilus Biotechnology, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Nautilus Biotechnology, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Nautilus Biotechnology, Inc.

20.85%

-0.57

114.33%

S&P 500

22.36%

1.70

13.18%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-16.94%

EBIT to Interest (avg)

-68.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.69

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

49.45%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.81

EV to EBIT

-5.10

EV to EBITDA

-5.65

EV to Capital Employed

5.94

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-116.44%

ROE (Latest)

-37.59%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

NET SALES(9M)

At USD 0.19 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Highest at USD -50.24 MM

NET PROFIT(HY)

Higher at USD -29.17 MM

-5What is not working for the Company

ROCE(HY)

Lowest at -36.21%

RAW MATERIAL COST(Y)

Grown by 58,368% (YoY

CASH AND EQV(HY)

Lowest at USD 179.9 MM

DEBT-EQUITY RATIO (HY)

Highest at -42.88 %

Here's what is working for Nautilus Biotechnology, Inc.

Net Sales

At USD 0.19 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD -50.24 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -29.17 MM

than preceding 12 month period ended Jun 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Nautilus Biotechnology, Inc.

Cash and Eqv

Lowest at USD 179.9 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -42.88 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 58,368% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales